 |
|
News About Influenza B Drug Resistance That Cannot Be Ignored
Anne Moscona, MD;
Jennifer McKimm-Breschkin, PhD
JAMA. 2007;297:1492-1493.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
During the last 2 years, the medical community has been tensely following the emergence of resistance to oseltamivir in strains of influenza A.1 The clinical relevance and transmissibility of these resistant variants has been unknown, and planning for epidemic and pandemic influenza thus far has ignored the issue due to lack of evidence that it will be of medical consequence. Neuraminidase inhibitors are presently the only reliable antiviral option for treatment of influenza infection: the usefulness of the adamantanes (amantadine and rimantidine) has been virtually eliminated by the development of resistance.2 Until now, little spontaneous resistance to neuraminidase inhibitors has been documented, and no spontaneously resistant influenza viruses were identified in the world prior to the introduction of the drugs. This may now be changing.
In this issue of JAMA, the report from Japan by Hatakeyama and colleagues3 documenting influenza B viruses with . . . [Full Text of this Article]
Author Affiliations: Departments of Pediatrics and Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY (Dr Moscona); and Molecular and Health Technologies, Parkville, South Victoria, Australia (Dr McKimm-Breschkin).
RELATED ARTICLE
Emergence of Influenza B Viruses With Reduced Sensitivity to Neuraminidase Inhibitors
Shuji Hatakeyama, Norio Sugaya, Mutsumi Ito, Masahiko Yamazaki, Masataka Ichikawa, Kazuhiro Kimura, Maki Kiso, Hideaki Shimizu, Chiharu Kawakami, Kazuhiko Koike, Keiko Mitamura, and Yoshihiro Kawaoka
JAMA. 2007;297(13):1435-1442.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Partial Resistance of Influenza B to Neuraminidase Inhibitors
JWatch General 2007;2007:1-1.
FULL TEXT
|
